Toledo Lalangui Carla Natali, Checa Altuna Tamara Anabel, Zabala Aguilar Mayra Alexandra, Ayala Brito Rosa Guadalupe, Goyes Mena Andrea Patricia, Casillas Flores Ricardo Alfredo, Vizcaíno Romero Alejandra Beatriz, Arévalo Jaramillo María Daniela


SUMMARY: The purpose of this review is to guide physicians in particular on the generalities to be taken into account
regarding the management of metastatic breast cancer for which pubmed and google scholar updated literature were
searched and basic concepts were established to help understand this topic.

Full Text:



Fietz T, Tesch H, Rauh J, Boller E, Kruggel L, Jänicke M, et al. Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study. The Breast [Internet]. 2017 Aug;34:122–30. Available from:

Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer 1985–2016. The Breast [Internet]. 2017 Feb;31:46–50. Available from:

Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ CK. Cancer Statistics Review, 1975-2013 - SEER Statistics. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD. 2015.

Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, et al. Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015). The Breast [Internet]. 2018 Jun;39:131–8. Available from:

Malmgren JA, Mayer M, Atwood MK, Kaplan HG. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat [Internet]. 2018 Jan 16;167(2):579–90. Available from:

Hölzel D, Eckel R, Bauerfeind I, Baier B, Beck T, Braun M, et al. Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry. J Cancer Res Clin Oncol [Internet]. 2017 Sep 20;143(9):1701–12. Available from:

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol [Internet]. Oxford University Press; 2018 Aug 1;29(8):1634–57. Available from:

Cundín DRO y DM, editor. Glosario del Cáncer. Aula Medic. Universidad del País Vasco; 2007. 02-103 p.

Gradishar WJ, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, et al. NCCN Guidelines Version 3.2019 Breast Cancer. In: NCCN Guidelines [Internet]. 2019. Available from:

Arslan C, Sari E, Aksoy S, Altundag K. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets [Internet]. 2011 Jan 24;15(1):21–30. Available from:

Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis. Oncologist [Internet]. 2010 Nov 1;15(11):1164–8. Available from:

Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH, et al. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. J Clin Oncol [Internet]. 2010 Dec 10;28(35):5132–9. Available from:

Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Cancer Netw [Internet]. 2009 Jun;7(Suppl_3):S-1-S-32. Available from:

Lacey D., Timms E, Tan H-L, Kelley M., Dunstan C., Burgess T, et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation. Cell [Internet]. 1998 Apr;93(2):165–76. Available from:

Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J. 2001;

Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer [Internet]. 2004 Jun;207–24. Available from:

Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol [Internet]. 1998 Jun;16(6):2038–44. Available from:

Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol [Internet]. 1996 Sep;14(9):2552–9. Available from:

Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer [Internet]. 2001 Apr 1;91(7):1191–200. Available from:

Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, et al. Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients. J Clin Oncol [Internet]. 2001 Jul 15;19(14):3434–7. Available from:

Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer. J Clin Oncol [Internet]. 2003 Nov 1;21(21):4042–57. Available from:

Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med [Internet]. 2012 Feb 9;366(6):520–9. Available from:

Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials. J Clin Oncol [Internet]. 2001 Jan 15;19(2):343–53. Available from:

Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial. J Clin Oncol [Internet]. 2000 Nov 15;18(22):3758–67. Available from:

Bonneterre J, Thürlimann B, Robertson JFR, Krzakowski M, Mauriac L, Koralewski P, et al. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol [Internet]. 2000 Nov 15;18(22):3748–57. Available from:

J.M. N, A. B, M. P, W. H, G. B, A. M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol. 2000;

Paridaens RJ, Dirix LY, Beex L V., Nooij M, Cameron DA, Cufer T, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;

Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase Inhibitors in the Treatment of Breast Cancer. Endocr Rev [Internet]. 2005 May 1;26(3):331–45. Available from:

Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer [Internet]. 2003 Nov;3(11):821–31. Available from:

Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev [Internet]. 2009 Oct 7; Available from:


  • There are currently no refbacks.